Yeming Wang to Severity of Illness Index
This is a "connection" page, showing publications Yeming Wang has written about Severity of Illness Index.
Connection Strength
0.104
-
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Dec; 62:103125.
Score: 0.030
-
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020 May 24; 21(1):422.
Score: 0.029
-
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021 Dec; 10(1):664-676.
Score: 0.008
-
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 01 16; 397(10270):220-232.
Score: 0.008
-
Risk Factors of Viral RNAaemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19. Chest. 2021 04; 159(4):1382-1386.
Score: 0.008
-
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect. 2021 Jan; 27(1):112-117.
Score: 0.007
-
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 09; 56(3).
Score: 0.007
-
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020 Oct; 14(5):601-612.
Score: 0.007